Health ❯ Healthcare

Cancer Research

Clinical Trials Immunotherapy Biomarkers Tumor Microenvironment Epidemiology Tumor Biology Clinical Studies Survival Rates Oncology Breast Cancer Innovative Therapies Therapeutics Early Detection Statistics Charity Organizations Treatment Resistance Pediatric Cancer Treatment Innovations Childhood Cancer Drug Development Fundraising Cancer Treatment Molecular Mechanisms Melanoma Epigenetics Risk Factors Innovations in Treatment Screening Methods Funding Therapeutic Strategies Tumor Immunology Genetic Mutations Metastasis Biotechnology Treatment Advances Patient Outcomes Diagnostic Methods Medical Facilities Lung Cancer Research Risk Assessment Patient Care Combination Therapy Solid Tumors Clinical Research Lymphoma Studies Genetic Research Genomics Public Health Genetics Resistance Mechanisms Leukemia Screening Tests Vaccine Development Recurrence Risk Treatment Options Rare Cancers Innovations Drug Efficacy Philanthropy Immune Response Innovative Treatments Survivorship Lung Cancer Therapeutic Targets Triple-Negative Breast Cancer Monoclonal Antibodies Cancer Statistics Treatment Strategies ASH Annual Meeting Therapies Diagnostic Challenges Glioma Artificial Intelligence Systematic Reviews Tumor Characteristics Genetic Diagnostics Pediatric Oncology Clinical Evidence Prostate Cancer Statistics Glioblastoma BCL-2 Inhibitors PIK3CA Mutations Charity Experimental Models Pharmaceuticals Dysplasia and Cancer Mortality Rates Urothelial Cancer Early Diagnosis Expert Opinions Screening Efficacy Data-Driven Solutions Preventive Medicine Trial Studies Tumor Targeting Proteomics Immunotherapy Agents Dysplasia Precision Medicine Prostate Cancer Research

Penn State THON Weekend Rolls On With Football NIL Pledge and Campbell Match

The 46-hour student marathon supports Four Diamonds, with final 2026 totals to be announced at Sunday’s close.

Grail Shares Plunge About 50% After NHS-Galleri Trial Misses Primary Endpoint

FDA Approves First All-Oral, Fixed-Duration First-Line CLL/SLL Regimen: Calquence Plus Venetoclax

Experts Call for Targeted Screening and Research on Lung Cancer in Never-Smokers

BMJ Study Finds Menstrual Blood Test Rivals Clinician Screening for HPV

AI-Backed Mammograms Cut Later Breast Cancer Diagnoses by 12% in Large Swedish Trial

New CAR T Strategy Targets Tumor Macrophages, Triggers Antitumor Immunity in Mice

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Kentucky Blood Center Opens Donations to More Cancer Survivors One Year After Treatment

Immune Atlas Sharpens Myeloma Risk Prediction as Dual-Target CAR T Counters BCMA Loss

Mount Sinai Deploys PRISM AI to Match Cancer Patients to Trials Systemwide

FDA Grants Accelerated Approval to Subcutaneous Lunsumio for Relapsed Follicular Lymphoma

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Dana-Farber to Pay $15 Million to Resolve DOJ Claims Over Manipulated Data in NIH-Funded Studies

Barkley, O’Neal Pledge $200,000 On-Air to Dick Vitale’s Pediatric Cancer Gala

Phase II Trial Finds 24 Gy Preoperative Radiation With Pembrolizumab Boosts T‑Cell Infiltration in HR+/HER2− Breast Cancer

Trial Finds Some Early Breast Cancer Patients Can Skip Sentinel Node Biopsy Without Harming 5-Year Control

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

AI Multimodal Model Outperforms Oncotype DX for Long-Term Breast Cancer Recurrence Risk